{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)","item":"https:\/\/www.regionalcancercare.org\/trials\/elacestrant-versus-standard-endocrine-therapy-in-women-and-men-with-node-positive-estrogen-receptor-positive-her2-negative-early-breast-cancer-with-high-risk-of-recurrence-a-global-multicenter\/#breadcrumbitem"}]}